logo
Share SHARE
FONT-SIZE Plus   Neg

Lexicon Phase 2 Trial Of Anti-Tumor Drug Meets Primary Endpoint, Begins Phase 3

Lexicon Pharmaceuticals, Inc. (LXRX), a biopharmaceutical company announced new data from its recently completed Phase 2 study of its investigational drug telotristat etiprate for carcinoid tumors. Through the trial, the drug achieved its primary endpoint that is the reduction of bowel movements from baseline at week 12 in 46.4 percent of the patients involved in the study and suffering from metastatic carcinoid syndrome. In addition, the company said it would present the data from the trial at the North American Neuroendocrine Tumor Society on October 13 in California.

Further, the company added Telotristat etiprate, administered orally was well tolerated by the patients with only three of the patients reporting serious adverse events, none of which was related to study drug.

In a statement, the company said it is also initiating a 12-week registrational Phase 3 trail that is designed to test the drug's safety, efficacy after its positive outlook in the Phase 2 trials, said Lexicon in a statement.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Health IQ Insurance Services, a startup focused on providing life insurance for health-conscious individuals, said it has secured $34.6 million in Series C funding, led by Andreessen Horowitz. To date, the company has raised a total of $81 million in funding mostly from its existing investors. General Motors Co. is recalling nearly 49,000 trucks worldwide to fix a fuel tank issue that can increase the risk of a fire. The recall covers Chevrolet Silverado 3500 and GMC Sierra 3500 trucks from the 2011 through 2015 model years, all equipped with dual fuel tanks. Meredith Corp. is reportedly in talks for the acquisition of Time Inc, with a staunch support from billionaire brothers Charles and David Koch. Des Moines-based Meredith is the publisher of Family Circle and Better Homes and Gardens and aims to acquire the publisher of Time, People and Fortune Magazines.
comments powered by Disqus
Follow RTT